Apatinib as a Third-Line Treatment for HER2-Positive Metastatic Gastric Cancer: A Multi-Center Single-Arm Cohort Study

Zhang Xin; Huo Haoran; Nie Yanan; Xue Jiadong; Yuan Zengjiang; Zhang Zhenyi

doi:10.5230/jgc.2022.22.e33

추천

검색

자료유형: 학술저널

저자정보: Zhang Xin (Department of General Surgery Handan Central Hospital Handan China.) Huo Haoran (Department of General Surgery Handan Central Hospital Handan China.) Nie Yanan (Endoscopy Room Han Gang Hospital Handan China.) Xue Jiadong (Department of General Surgery Handan Central Hospital Handan China.) Yuan Zengjiang (Department of General Surgery Handan Central Hospital Handan China.) Zhang Zhenyi (Department of General Surgery Handan Central Hospital Handan China.)

저널정보: 대한위암학회 Journal of Gastric Cancer Journal of Gastric Cancer 제22권 제4호

발행연도: 2022.10

수록면: 408 - 417 (10page)

DOI: 10.5230/jgc.2022.22.e33

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose Treatment options are limited after the failure of first-and second-line treatments in patients with HER2+ metastatic gastric cancer (mGC). The present study aimed to explore the efficacy, safety, and prognostic factors of apatinib efficacy as a third-line therapy for patients with human epithelial growth factor receptor 2-positive (HER2+) mGC. Materials and Methods A total of 59 HER2+ mGC patients who received apatinib as third-line therapy were retrospectively enrolled in this two-center, single-arm, cohort study; the clinical response, survival data, and adverse events were retrieved. Results The median progression-free survival (PFS) was 5.2 months (95% confidence interval [CI], 3.9–6.5), and the median overall survival (OS) was 8.2 months (95% CI, 6.6–9.8) Furthermore, forward stepwise multivariate Cox regression analysis showed that a higher Eastern Cooperative Oncology Group performance status score and multiple metastases were independently correlated with decreased PFS and OS (both P<0.05). The main adverse events were leukopenia (45.8%), hypertension (44.1%), thrombocytopenia (39.0%), hand-foot syndrome (37.3%), and elevated transaminase (33.9%). Grade 3 adverse events mainly included hypertension (5.1%) and neutropenia (5.1%); grade 4 adverse events did not occur. Conclusions Apatinib is efficient and well tolerated in patients with HER2+ mGC as a third-line treatment, suggesting that it may be a candidate of choice for these patients.

#Apatinib #Gastric cancer #Prognosis #Mortality #Safety

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!